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ORIGINAL ARTICLE
Electrophysiological and Hemodynamic Effects of
Vernakalant and Flecainide During Cardiac
Resynchronization in Dyssynchronous Canine Hearts
Lars B. van Middendorp, MD,*† Marc Strik, MD,* Patrick Houthuizen, MD,* Marion Kuiper, BSc,*
Jos G. Maessen, MD, PhD,† Angelo Auricchio, MD, PhD,‡ and Frits W. Prinzen, PhD*
Introduction: Patients with heart failure and left bundle branch
block (LBBB) are frequently treated with biventricular pacing
(BiVP). Approximately one-third of them suffer from atrial ﬁbrilla-
tion. Pharmacological conversion of atrial ﬁbrillation is performed
with drugs that slow ventricular conduction, but the effects of these
drugs on the beneﬁt of BiVP are poorly understood.
Methods: Experiments were performed in dogs with chronic
LBBB, investigating the effects of Vernakalant and Flecainide
(n = 6 each) on hemodynamics and electrophysiology during epicar-
dial (EPI) and endocardial BiVP. The degree of dyssynchrony and
conduction slowing was quantiﬁed using QRS width and EPI elec-
trical mapping.
Results: Compared with LBBB, EPI and endocardial BiVP reduced
QRS duration by 7% 6 9% (P , 0.05 compared with LBBB) and
20% 6 13% (P , 0.05 compared with LBBB, P , 0.05 between
modes), respectively. During BiVP, the administration of Vernakalant
and Flecainide increased QRS duration by 20% 6 14% (P , 0.05
compared with predrug BiVP) and 34% 6 10% (P , 0.05 compared
with predrug BiVP, P , 0.05 between drugs). left ventricular (LV)
dP/dtmax decreased by 16%6 8% (P , 0.05 compared with predrug
BiVP) during Vernakalant and by 14% 6 15% (P , 0.05 compared
with predrug BiVP) during Flecainide. The drugs did not affect the
relative changes in QRS width and LV dP/dtmax induced by BiVP.
Conclusions: Vernakalant and Flecainide decrease contractility,
slow myocardial conduction velocity, and increase activation time.
The electrical and hemodynamic beneﬁts of BiVP are not altered by
the drugs.
Key Words: Vernakalant, Flecainide, cardiac resynchronization
therapy, dyssynchrony, atrial ﬁbrillation
(J Cardiovasc Pharmacol 2014;63:25–32)
INTRODUCTION
Cardiac resynchronization therapy (CRT) has been
shown to reduce morbidity and mortality in patients with
mild to severe heart failure (HF) and dyssynchrony.1 Despite
CRT’s improvement in symptoms and left ventricular ejection
fraction, the risk of developing paroxysmal or persistent atrial
ﬁbrillation (AF) remains high.2 This encompasses the clinical
dilemma whether patients who show increase in left ventric-
ular ejection fraction and a reduction in ventricular volumes
(in some cases even normalization) may be treated with anti-
arrhythmic drugs, such as Flecainide or Vernakalant, for phar-
macological cardioversion because both are contraindicated
in HF.3,4 Both drugs are indeed capable of rapidly converting
recent-onset AF into sinus rhythm,5 whereas Flecainide can
also be used to prevent episodes of paroxysmal AF after
direct current cardioversion.6,7 Compared with Flecainide,
Vernakalant is relatively atrial selective; it acts on all phases
of the action potential by blocking the potassium currents
IKur, IKACh, Ikr, and Ito and the sodium channel INa, but it
has little effect on the IK1 and IKs receptors.
8 Thus, at least in
theory, Vernakalant may be preferred to Flecainide in patients
with moderate left ventricular (LV) dysfunction.
Clinical evidence about interference of Vernakalant and
Flecainide with CRT is not available because these patients
are commonly excluded in AF studies. Therefore, it is
clinically relevant to test, in a preclinical model, the potential
interference of antiarrhythmic drugs with the positive inotro-
pic effect elicited by CRT.
In the present study, we investigated the effects of
Vernakalant and Flecainide, during acute biventricular pacing
(BiVP), on ventricular function and conduction in an estab-
lished canine model of chronic dyssynchrony presenting with
moderately depressed left ventricular systolic function.9 Exten-
sive electrical mapping and hemodynamic measurements were
performed before and after infusion of either Vernakalant or
Flecainide during conventional epicardial (EPI) and novel
endocardial (ENDO) BiVP. We tested both pacing modalities
because our previous studies showed that ENDO BiVP acti-
vates the LV in a more physiological manner and further im-
proves LV function when compared with EPI BiVP.10,11
METHODS
Animal handling was performed according to the Dutch
Law on Animal Experimentation and the European Directive
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for the Protection of Vertebrate Animals used for Experi-
mental and Other Scientiﬁc Purposes (86/609/EU). The
protocol was approved by the Experimental Animal Com-
mittee of Maastricht University.
Experimental Models
The experiments were performed on 12 adult mongrel
dogs of either sex, weighing 21.7 6 4.4 kg. After induction
with sodium thiopental, anesthesia was maintained by continu-
ous infusion of Midazolam (0.25 mg$kg21$h21) and Sufentanil
(3 mg$kg21$h21). During a sterile closed-chest procedure, left
bundle branch block (LBBB) was induced by radiofrequency
ablation as described in detail previously.12 Final experiments
were performed 16–18 weeks after the onset of LBBB. At that
time, the animals were given the same anesthesia as used during
the ﬁrst procedure.
Experimental Methods
Right ventricular (RV) and LV pressures were measured
by a 7-Fr catheter tip manometer (CD-Leycom, Zoetermeer, the
Netherlands). An RF Marinr catheter (Medtronic, Heerlen, the
Netherlands) was advanced into the right atrium to pace at
a ﬁxed atrial rate (atrial paced, atrial sensed, inhibited pacing) at
approximately 10 beats per minute above the intrinsic rhythm.
Surface electrocardiogram (ECG) was derived from the limb
leads.
After a thoracotomy, 2 multielectrode arrays containing
102 electrodes were placed epicardially. The ﬁrst array was
placed around the base of the heart, and the second was
placed around the mid level. Both the arrays were used to
measure local RV and LV electrograms. One of the electrodes
positioned at the mid level of the LV free wall was used as
EPI pacing electrode. Its 4 neighboring electrodes were used
to calculate conduction velocity. In addition, an ENDO
plunge electrode was placed at the mid LV lateral wall for
ENDO pacing. Apical electrograms were measured by
a small array of 4 electrodes. A multielectrode catheter
(Daig Livewire TC, Minnetonka, MN) was positioned in the
RV to record septal electrograms and simultaneously pace
the RV apex.
Infusion Protocol
Dogs were arbitrarily assigned to receive Vernakalant
(n = 6) (MSD, West Point, PA) or Flecainide (n = 6) (Meda
Pharma B.V., Amstelveen, the Netherlands). Both the drugs
were given in a 2-dose regime. The ﬁrst dose of Vernakalant
was given using slow infusion of 5.7 mg/kg in 15 minutes,
followed by an interval of 15 minutes before the second dose.
The second dose contained 2.3 mg/kg and was similarly given
over a 15-minute period. The aim of the split dosing regimen
was to achieve the target dose within 15 minutes and maintain
this target for the next 45 minutes. To verify concentration
levels of Vernakalant, plasma samples were collected right
after the ﬁrst and second doses and analyzed at Cardiome
Pharma Corp (Vancouver, Canada). The ﬁrst dose of Flecai-
nide, 1.5 mg/kg, was administered over a 10-minute period.
The second dose, 2.5 mg/kg, was given correspondingly, after
a 15-minute interval. These doses are comparable with the
previously used concentrations of Flecainide in canine
experimental models and are expected to reach a concentration
of 1.8 · 1025 mM.13,14
Hemodynamic status was continuously monitored
throughout the protocol. Five minutes before the administra-
tion of both the drugs and within 5 minutes after ﬁnal
administration, hemodynamic and electrophysiological ef-
fects of BiVP were assessed and compared with LBBB
(AAI pacing). BiVP was performed by pacing the RV apex
either in combination with an EPI electrode on the LV mid
lateral wall (EPI BiVP) or in combination with the LV ENDO
electrode (ENDO BiVP). A ﬁxed short AV delay (80–100
ms) was chosen to ensure full capture. VV interval was set
to 0 ms. ENDO BiVP and EPI BiVP were randomly assigned.
Each pacing modality was allowed to stabilize for a minute
before hemodynamic and electrophysiological measurements
were started.
Data Analysis
Depolarization times were calculated for each individ-
ual electrode as the difference between the onset of activation
(ventricular pacing artifact during BiVP or Q wave during
AAI pacing) and the time of steepest negative deﬂection in
the electrogram (2dV/dt). Total activation time (AT) was
deﬁned as the difference between the shortest and longest
depolarization times. ECG parameters were extracted from
the surface ECG. Although QRS width and total AT reﬂect
overall electrical dyssynchrony, they do not express the spa-
tial progression of the electrical wave front. For that purpose,
AT vectors (ATV) were calculated in a short-axis circumfer-
ence using the values of the depolarization times of all the
electrodes.15 The degree of dyssynchrony was expressed as
the ATV amplitude (milliseconds) and the main direction of
conduction as the ATV angle (degree). Angles were measured
from the reference vector between the RV free wall (0 degree)
anterior LV (90 degree) and LV free wall (180 degree) with
the aid of custom MATLAB software (MathWorks, Natick,
MA). During EPI BiVP, conduction velocity could be esti-
mated by averaging the dividend of the ATs of 4 neighboring
electrodes and their known ﬁxed distances.10
Mechanical interventricular dyssynchrony (MIVD) was
assessed from the time difference of the upslope of normal-
ized LV and RV pressures.12 Hemodynamic data were ana-
lyzed as described previously with the aid of custom
MATLAB software.16 LV dP/dtmax, the maximal ﬁrst deriv-
ative of LV pressure, is a common index of contractility.
Statistical Analyses
Data are presented as mean 6 SD. Statistical analysis
was performed using Statistical Package for Social Sciences
for Windows version 20.0 (SPSS Inc., Chicago, IL). The
effects of EPI and ENDO BiVP after Vernakalant or Flecai-
nide were analyzed using linear mixed-effect models. This
method is also known as multilevel analysis or mixed-effect
analysis. The random intercept corrects for the correlation
between repeated measurements. The least squared differen-
ces correction was used for post hoc comparisons. A paired
sample t test was used for a head-to-head comparison between
ENDO and EPI BiVP neglecting drug or dose. A 2-sided
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probability value of P # 0.05 was considered statistically
signiﬁcant.
RESULTS
Data from a previous study showed that in the animal
preparation used, all electrical and hemodynamic variables
are essentially constant over a 45-minute duration of the
protocol (Table 1).15 No statistical differences were noted in
baseline values between the Vernakalant and the Flecainide
groups.
In 11 of the 12 experiments, the effects of ENDO and
EPI BiVP were evaluated at baseline and after the second
dose of the drugs. One dog in the Flecainide group died
during the infusion of the second dose because of cardiogenic
shock.
Plasma levels of Vernakalant reached the desired
exposure target of 3 mg/mL (3.7 6 0.8 mg/mL). This concen-
tration is equal to 1.125 mM. There was no signiﬁcant dif-
ference between plasma concentrations after the ﬁrst and
second doses.
Electrophysiological Effects
The electrical activation map in the left panel of Figure 1
shows a typical LBBB-type activation pattern, which starts in
the RV, then progresses, through to septum, around the LV,
and ﬁnally activates the LV lateral basal wall. ENDO and EPI
BiVP reverse this conduction pattern by early activation of the
LV lateral wall from which activation spreads toward the sep-
tum colliding with the activation wave front originating from
the RV apex electrode (middle and right panels).
During AAI pacing, both the drugs signiﬁcantly
increased QRS width (by 17% 6 13% vs. 34% 6 15% for
Vernakalant vs. Flecainide) (Table 2). During BiVP, the drugs
caused a similar relative increase in QRS width (20% 6 14%
vs. 34% 6 10% for Vernakalant vs. Flecainide) when com-
pared with predrug BiVP (Fig. 2, lower panel). Still, BiVP
caused a similar and constant reduction in QRS width as com-
pared with AAI pacing (Fig. 3, lower panel). ENDO BiVP
reduced dyssynchrony signiﬁcantly more than EPI BiVP
(P , 0.05). Conduction velocity, calculated during EPI BiVP,
was signiﬁcantly reduced by Flecainide, but only a trend
toward reduction was seen after Vernakalant administration
(Table 2).
During AAI pacing, the ATV angle pointed toward the
LV lateral wall (180 degree). The ATV angle did not change
signiﬁcantly after the infusion of either drug, but the ATV
amplitude tended to increase after Vernakalant and increased
signiﬁcantly after Flecainide. BiVP changed the ATV angle
toward an angle between the RV wall (0 degree) and the
anterior LV wall (90 degree), indicating a main direction of
conduction from the LV toward the RV. Besides a change in
ATV angle, ATV amplitude decreased considerably on BiVP,
reﬂecting a more synchronous activation pattern. After
infusion of both Vernakalant and Flecainide, no signiﬁcant
changes were observed in either ATV angle or amplitude
during BiVP (Table 2, Fig. 4).
Both the drugs prolonged intrinsic PQ time by approx-
imately 17%. During BiVP, PQ time remained equal because
a ﬁxed AV delay was used. During AAI pacing and during
BiVP, no signiﬁcant effect on QT corrected for heart rate
interval was observed, nor were any arrhythmias detected.
Hemodynamic Effects
Associated with the slower electrical conduction
induced by the drugs, MIVD increased signiﬁcantly after
Flecainide and tended to increase after Vernakalant.
Conversely, BiVP lowered MIVD, indicating mechanical
resynchronization. This mechanical resynchronization was
more pronounced for ENDO BiVP than for EPI BiVP
(Table 2).
During AAI pacing, Vernakalant and Flecainide
decreased LV dP/dtmax by 17% 6 4% and 15% 6 9%,
respectively. Similar relative reductions in LV dP/dtmax were
noted during EPI and ENDO BiVP, with decreases of 16% 6
8% in the Vernakalant group and 14% 6 15% in the Flecai-
nide group (Table 3, Fig. 2). BiVP increased LV dP/dtmax by
approximately 15%, independent of the presence, dose, and
kind of drug (Fig. 3), the absolute increase being 127 6 26
mm Hg/s during EPI BiVP and 161 6 44 mm Hg/s during
ENDO BiVP. Combining data collected during the adminis-
tration of both drugs, LV dP/dtmax increased signiﬁcantly
more during ENDO than during EPI BiVP (P , 0.05).
EPI and ENDO BiVP had no signiﬁcant inﬂuence on
LV systolic pressure (Table 3). Vernakalant decreased LV
systolic pressure to levels slightly, but not signiﬁcantly,
below predrug values, whereas Flecainide did decrease
LV systolic pressure signiﬁcantly below predrug values.
Nevertheless, even for Flecainide, the reduction in LV
systolic pressure was modest with an average decrease of
5 mm Hg (Table 2).
Both drugs reduced LV dP/dtmin and Tau, an index of
LV isovolumic relaxation, but this was hardly affected by
ENDO or EPI BiVP (Table 3). Effects of both drugs on RV
pressure were small (Table 1). EPI and ENDO BiVP caused
an insigniﬁcant reduction in RV systolic pressure (Table 2).
TABLE 1. Hemodynamic and Electrical Activation Data During
45 Minutes in a Historical Control Group Undergoing Various
Pacing Settings
Control
AAI Pacing
T = 0 min T = 45 min
Heart rate, bpm 136 6 11 144 6 15*
QRS width, ms 97 6 12 96 6 15
PQ time, ms 141 6 35 137 6 32
QTc, ms 355 6 17 353 6 19
Total AT, ms 80 6 16 82 6 17
LV systolic pressure, mm Hg 78 6 16 79 6 12
LV diastolic pressure, mm Hg 3 6 3 4 6 3
LV dP/dtmax, mm Hg/s 1187 6 212 1214 6 142
LV dP/dtmin, mm Hg/s 21199 6 320 21277 6 303
RV systolic pressure, mm Hg 23 6 12 26 6 13
RV diastolic pressure, mm Hg 8 6 5 8 6 4
*P , 0.05 compared with T = 0 min.
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FIGURE 1. Activation maps derived from the EPI electrode arrays and plotted on a 3D model of the LV and RV epicardium as
previously reported.10 Dotted circles represent the EPI electrode arrays. Typical examples are shown of a dyssynchronous acti-
vation pattern during LBBB (left panel) and a more synchronous activation pattern during EPI BiVP (middle panel) and ENDO BiVP
(right panel) at baseline.
TABLE 2. Hemodynamic and Electrical Activation Data During ENDO and EPI BiVP After Infusion of Vernakalant and Flecainide
Vernakalant
AAI Pacing EPI BiVP ENDO BiVP
Predrug Drug Predrug Drug Predrug Drug
Heart rate, bpm 147 6 3 147 6 3 147 6 3 149 6 5 148 6 3 145 6 9
QRS width, ms 89 6 3 103 6 10* 84 6 12 94 6 12* 76 6 13 87 6 10*
QTc, ms 350 6 10 361 6 9 360 6 16 372 6 10 350 6 20 369 6 24
Total AT, ms 90 6 10 96 6 3* 73 6 8 81 6 12 70 6 18 65 6 9
Conduction velocity, m/s NA NA 0.85 6 0.10 0.79 6 0.12 NA NA
ATV angle, degree 178 6 8 179 6 10 84 6 62 87 6 68 60 6 58 43 6 50
ATV amplitude, ms 63 6 10 69 6 10 35 6 21 39 6 25 27 6 16 24 6 15
MIVD, ms 218 6 1 222 6 3 212 6 8 215 6 11 28 6 3 21 6 3‡
LV systolic pressure, mm Hg 86 6 15 82 6 16 81 6 14 77 6 16* 82 6 14 79 6 18*
LV end diastolic pressure, mm Hg 8 6 1 9 6 2* 8 6 4 8 6 3 7 6 3 7 6 2
LV dP/dtmax, mm Hg/s 1257 6 373,373 1054 6 336* 1346 6 257 1208 6 218* 1414 6 493 1249 6 234*
LV dP/dtmin, mm Hg/s 21494 6 404 21236 6 433* 21359 6 420 21224 6 460* 21363 6 417 21238 6 453*
RV systolic pressure, mm Hg 48 6 14 43 6 11* 40 6 7 37 6 6* 38 6 7 36 6 6*
RV diastolic pressure, mm Hg 11 6 5 12 6 8 8 6 4 8 6 3 9 6 5 10 6 5
Tau, ms 35 6 15 37 6 6 38 6 3 41 6 5 36 6 3 40 6 5
Flecainide
AAI Pacing EPI BiVP ENDO BiVP
Predrug Drug Predrug Drug Predrug Drug
Heart rate, bpm 151 6 15 150 6 4 151 6 16 149 6 4 151 6 16 150 6 3
QRS width, ms 96 6 13 126 6 19*† 82 6 13 114 6 7*† 74 6 11 102 6 7*‡
QTc, ms 358 6 30 394 6 25 350 6 27 364 6 16 339 6 24 365 6 13
Total AT, ms 87 6 12 117 6 20* 70 6 23 88 6 16* 65 6 19 74 6 14*
Conduction velocity, m/s NA NA 0.85 6 0.25 0.63 6 0.12‡ NA NA
ATV angle, degree 194 6 18 196 6 16 31 6 23 34 6 23 39 6 35 19 6 17
ATV amplitude, ms 58 6 6 78 6 11* 23 6 8 31 6 19 24 6 20 19 6 13
MIVD, ms 232 6 9 237 6 15* 217 6 5 217 6 6 213 6 9 216 6 12†
LV systolic pressure, mm Hg 77 6 6 72 6 6*† 78 6 4 74 6 6* 78 6 4 75 6 5*
LV end diastolic pressure, mm Hg 13 6 5 14 6 4 9 6 7 10 6 8 8 6 6 9 6 8
LV dP/dtmax, mm Hg/s 1224 6 323 978 6 231* 1400 6 400 1123 6 303* 1443 6 389 1131 6 319*
LV dP/dtmin, mm Hg/s 21382 6 444 21134 6 272* 21386 6 465 21205 6 372* 21379 6 454 21191 6 387*
RV systolic pressure, mm Hg 36 6 7 33 6 7 33 6 6 30 6 7 32 6 6 30 6 6
RV diastolic pressure, mm Hg 8 6 9 9 6 8 11 6 8 12 6 8 10 6 7 11 6 7
Tau, ms 37 6 11 41 6 6 40 6 13 47 6 6 40 6 12 48 6 9
*P , 0.05 compared with predrug.
†P , 0.05, Flecainide compared with Vernakalant at the same dosage level.
‡P , 0.05, ENDO compared with EPI pacing.
NA, not available.
van Middendorp et al J Cardiovasc Pharmacol  Volume 63, Number 1, January 2014
28 | www.jcvp.org  2013 Lippincott Williams & Wilkins
Relation Between Electrical Dyssynchrony
and Pump Function
The various conditions that inﬂuence electrical dyssyn-
chrony (drugs that slow impulse conduction to a variable
amount, BiVP in 2 different modes, and the combination with
each other) offer the opportunity to evaluate the relation
between electrical dyssynchrony and pump function over
a wide range of conditions. Figure 5 depicts a close relation
between QRS width and LV dP/dtmax, regardless of the way
the QRS width is achieved. For example, similar LV dP/
dtmax values were observed in the Vernakalant group during
baseline LBBB and ENDO BiVP after drug administration.
DISCUSSION
The present study shows that, in BiV paced ventricles,
Vernakalant and Flecainide slow down myocardial conduc-
tion, prolong electrical activation, and concordantly decrease
LV contractility. However, the beneﬁcial effects of both EPI
and ENDO BiVP are preserved during the administration of
these drugs. In all these conditions, ENDO BiVP reduces
dyssynchrony more than EPI BiVP.
Electrophysiological Effects
In this canine model of proximal LBBB, the impulse
conduction in the LV is entirely dependent on slow cell-to-
cell conduction within the “working myocardium” rather than
the rapid Purkinje system. This is true for the condition of
proximal LBBB but even more for BiVP, where relatively
slow cell-to-cell conduction in the working myocardium acti-
vates both the RV and the LV. The decrease in conduction
velocity observed for both drugs is in line with the increase in
total AT, ATV amplitude, and QRS width, whereas the unal-
tered ATV angle indicates that this conduction slowing oc-
curs uniformly. The observation that neither drug
signiﬁcantly changed ATV amplitude during BiVP implicates
that both EPI and ENDO BiVP reduce electrical dyssyn-
chrony to a similar extent for the entire range of conduction
velocities investigated.
The similar relative changes in the aforementioned
variables during EPI and ENDO BiVP are interesting because
a previous study demonstrated that during ENDO BiVP,
a considerable part of ventricular activation occurs through
early involvement of conduction through more rapidly
conducting ENDO LV layers.10 Accordingly, the data from
the present study indicate that both drugs slow conduction in
all layers in the LV wall to a similar extent. This implicates
that Vernakalant also has a potent effect on sodium currents,
which is in line with a recent study by Wettwer et al17 that
strongly suggests that the main mode of action of Vernakalant
is through the blockage of sodium channels instead of the
assumed more potent and atrial selective blockage of IKur.
The importance of a small ATV amplitude has been
described in earlier studies of our group and is linked to
optimal hemodynamic response.15,18 The present study also
supports our earlier data that ENDO BiVP is to be favored
over conventionally applied EPI BiVP with respect to indices
of electrical dyssynchrony and pump function.10
The relative increase in QRS width by Vernakalant
and Flecainide observed in the present study is comparable
with that in the previously reported studies that have
FIGURE 2. LV dP/dtmax (top) and QRS width (bottom) dur-
ing intrinsic ventricular conduction (AAI pacing), EPI, and
ENDO BiVP for both Vernakalant and Flecainide. Because the
smallest QRS width goes hand in hand with the highest con-
tractility, the arrangement of plotting is reversed between the
top and bottom panels. SDs are mentioned in Table 1. #P ,
0.05 compared with predrug; †P , 0.05, Flecainide compared
with Vernakalant at the same dosage level; and *P , 0.05,
ENDO compared with EPI pacing.
FIGURE 3. Relative increase in LV dP/dtmax (top) and QRS
width (bottom) during EPI and ENDO BiVP for both Verna-
kalant and Flecainide with respect to LBBB (AAI pacing). SDs
are mentioned in Table 2. #P , 0.05 compared with AAI.
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predominantly been performed in patients with normal
ventricular conduction.19,20 This similarity may be explained
by a similar reduction in conduction velocity of the rapid
Purkinje system and the working myocardium.21 Yet, the
slower conduction is likely to have stronger implications in
hearts with abnormal conduction, such as during LBBB and
likewise during BiVP.
Hemodynamic Effects
In the present study, 2 factors modify the electrical
activation in the LBBB heart: BiVP and both drugs. It is well
known that BiVP resynchronizes the heart and that this is
associated with improved ventricular contractile function. The
opposite holds true for Vernakalant and Flecainide because
they slow down the ventricular conduction and thus
FIGURE 4. Color-coded activation
sequence in a short-axis section at
the level of the EPI electrode arrays
as depicted in Figure 2. Data are
represented as bull’s-eye plots, the
most basal regions being repre-
sented in the most outward layer.
0 degree and 180 degree indicate
the lateral wall of the RV and LV,
respectively, and 90 degree the
anterior wall. Arrows represent the
vector direction and amplitude, as
calculated from the ATs. ATV ampli-
tude values are mean 6 SDs of the
averages of the entire groups.
TABLE 3. Percent Difference From LBBB (AAI Pacing), MIVD, and LV End Diastolic Pressure Are Expressed as Absolute Difference
Vernakalant Flecainide
EPI BiVP ENDO BiVP EPI BiVP ENDO BiVP
Predrug Drug Predrug Drug Predrug Drug Predrug Drug
Heart rate 100 6 0 101 6 2 100 6 0 101 6 2 100 6 0 99 6 2 100 6 0 100 6 0
QRS width 94 6 12 94 6 10* 81 6 14* 87 6 10* 88 6 16* 93 6 9 80 6 13* 83 6 10*
QTc 103 6 4 103 6 3 99 6 5 102 6 7 99 6 7 99 6 8 97 6 6 99 6 10
Total AT 81 6 8* 83 6 11*† 71 6 13* 67 6 9* 69 6 18* 77 6 20*† 67 6 17* 64 6 12*
ATV direction 47 6 37 52 6 47 34 6 43 27 6 35 16 6 11 18 6 12 21 6 20 10 6 9
ATV amplitude 56 6 20 51 6 24 38 6 29 26 6 15 24 6 16 31 6 25 30 6 23 22 6 13
MIVD 7 6 10 7 6 9 13 6 10 20 6 7 16 6 5 21 6 12 19 6 6 24 6 14
LV systolic pressure 102 6 5 99 6 2 102 6 6 100 6 2 101 6 2 103 6 5 101 6 3 103 6 5
LV end diastolic pressure 1 6 3 21 6 1* 1 6 3 21 6 1* 21 6 1 0 6 1 21 6 1 0 6 1
LV dP/dtmax 110 6 6* 110 6 8 112 6 9 114 6 7* 114 6 5* 114 6 16 118 6 2* 115 6 13*
LV dP/dtmin 99 6 4 98 6 4 99 6 4 100 6 7 100 6 4 106 6 12 100 6 6 105 6 16
RV systolic pressure 93 6 5 93 6 5 89 6 8 90 6 7 92 6 6 90 6 8 89 6 10 90 6 10
RV diastolic pressure 91 6 30 92 6 33 110 6 18 103 6 51 113 6 34 110 6 28 101 6 20 108 6 29
*P , 0.05 compared with AAI.
†P , 0.05 versus ENDO BiVP.
van Middendorp et al J Cardiovasc Pharmacol  Volume 63, Number 1, January 2014
30 | www.jcvp.org  2013 Lippincott Williams & Wilkins
effectively desynchronize the ventricles, which is associated
with reduced contractility. On the other hand, sodium channel
blockers may directly act negative intropic, and thus the
observed decrease in contractility is potentially not related to
the decrease in conduction velocity. In this regard, it is
interesting that a recent study in isolated trabeculae from
explanted human hearts did not ﬁnd a negative inotropic
effect of Vernakalant.22 An important difference between iso-
lated papillary muscle preparations and our in vivo model is
that the muscles are ﬁeld stimulated and, therefore, are not
dependent on conduction. Nevertheless, BiVP can be consid-
ered to counteract the reduction in contractility that is caused
by the drugs irrespective of the mechanism by which contrac-
tility is decreased. An important and interesting observation
in this study is that the relative increase in LV dP/dtmax
because of BiVP is not inﬂuenced by administration of the
drugs. This implies that during BiVP, the tolerance for the
negative effects of both drugs on dyssynchronous failing
hearts may be larger. This observation is important because
episodes of hypotension have been described for HF patients
receiving Vernakalant and Flecainide.23,24
An important observation is the effects of uniformly
slowed conduction velocity on paced ventricles. Although
this slow conduction is created pharmacologically, it may also
help to improve our insight in the effect of CRT in hearts with
slow conduction by other mechanisms, such as (uniform)
ﬁbrosis or reduced expression of gap junctions. Although
drug-induced increased ATs coincide with proportional
reduction in contractility, the 2 modes of BiVP provide 2
“doses” of resynchronization that proportionally oppose the
conduction slowing effects. One of the implications of these
data may be that hearts with wider QRS complexes may
require better resynchronization to achieve a good pump func-
tion, and in these hearts, ENDO CRT may thus be indicated.
The other implication is that for a given mode of
resynchronization, the effect is proportional to the degree of
resynchronization, independent of the prevailing conduction
velocity.
Comments on the Experimental Model
The chronic LBBB dog model shows moderately
reduced left ventricular function and hypertrophy but is not
associated with clinical symptoms of HF. This, however, best
reﬂects the clinical situation of patients who signiﬁcantly
improved after CRT. On the other hand, it may explain why
the drugs affect blood pressure only to a minimal amount
because cardiac reserve and autonomic reﬂexes may com-
pensate drug-induced hypotension.
We speciﬁcally paced at a ﬁxed atrial rate to ascertain
that the observed hemodynamic and electrical changes were
not inﬂuenced by alterations in heart rate. It is also important
to consider that these data have been acquired in anesthetized
animals. It is not known as to whether Midazolam/Sufentanil
anesthesia modulates the effects reported here or whether the
effects are reproducible in awake animals.
Of course, the results of the present in vivo animal
study require conﬁrmation in patients to properly judge their
clinical relevance. Furthermore, the effects of BiVP presented
here are acute and serve as surrogate for the long-term
alterations achieved in patients who are chronically treated
with CRT.
CONCLUSIONS
Vernakalant and Flecainide decrease contractility, slow
myocardial conduction velocity, and increase AT. However,
the electrical and hemodynamic beneﬁts of BiVP are not
altered by the drugs, the effect being more pronounced for
ENDO BiVP than for EPI BiVP.
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